Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Alamos Gold -- Ignore unavailable to you. Want to Upgrade?

To: Rocket Red who wrote (701)	12/7/2001 11:37:30 PM
From: Stephen O	Read Replies (1) \| Respond to of 4470

I'll try HSE Husky this week. I sense that the takeover is very near.

To: Rocket Red who wrote (701)	12/8/2001 9:56:43 AM
From: Al Collard	Respond to of 4470

Hi Red, Your in with IEX-t @$7.58 for 2,638 shares. Chart for Inex Pharmaceuticals Corp: stockcharts.com[l,a]djcanimy[dc][pc20!b50!b100!b200!f][vc60][iUb14!Ll14!La12,26,9!Lh14,3!Lc20] From the chart of IEX we can see the stock has been in a nice uptrend for the past month and should have good support @$6.73 it's 20EMA. The chart indicators are bullish and pointing up. It will be interesting to see how the market re-acts to the additional 6 million common shares that IEX will be trading starting next week. Good luck with this pick, Al

To: Rocket Red who wrote (701)	12/12/2001 8:48:29 AM
From: Al Collard	Respond to of 4470

IEX-t...in the news: Globe says Stewart favours Inex Pharmaceuticals Wed 12 Dec 2001 The Globe and Mail reports in its Wednesday, Dec. 12, edition that Tera Capital fund manager Duncan Stewart, a value-oriented manager who runs StrategicNova Canadian Technology Fund, believes Inex Pharmaceuticals offers good value. The Globe's Shirley Won writes in the Best Bets column that Mr. Stewart believes the Nasdaq composite index could rise another 20 per cent to 2,400 points by spring. He says: "The fourth quarter is historically a very strong period. I believe that many companies are going to meet or beat expectations. In that sort of climate, stocks go up." With that in mind, Mr. Stewart recommends Inex Pharmaceuticals. The biopharmaceutical company, whose shares closed Tuesday on the Toronto Stock Exchange at $7.35, traded at a 52-week low of $3.26 in April and a 52-week high of $7.58 last Friday. Mr. Stewart says that Inex, which has a proprietary technology to improve cancer therapies, has executed partnerships this year with major players such as GlaxoSmithKline and Elan. He estimates that Inex stock could reach $15 over one year.

To: Rocket Red who wrote (701)	12/13/2001 9:00:39 AM
From: Al Collard	Respond to of 4470

IEX-t...in the news Inex Pharmaceuticals Closes $43.0 Million Bought Deal Financing VANCOUVER, Dec. 13 /CNW/ - Inex Pharmaceuticals Corporation (the "Company" or "INEX"; TSE: IEX) announced today the closing of its offering of 6,145,000 Common Shares at a price of $7.00 per share, in connection with the previously announced agreement with an underwriting syndicate led by BMO Nesbitt Burns Inc., and including Raymond James Ltd., RBC Dominion Securities Inc., Yorkton Securities Inc. and Dlouhy Merchant Group Inc. The gross proceeds of the offering are $43,015,000. The financing is a part of the company's overall strategic plan to evolve from a successful development stage biotechnology company to a specialty pharmaceutical company that can take products from the laboratory to the marketplace. The use of proceeds from the financing will be used to continue to invest and broaden the clinical and commercial opportunity for INEX's lead product, Onco TCS, as well as to accelerate and expand opportunities in the company's pipeline.